Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER versus HEPATAMINE 8.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER versus HEPATAMINE 8.
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER vs HEPATAMINE 8%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 4.25% w/ Electrolytes in Dextrose 25% is a parenteral nutrition formulation providing amino acids for protein synthesis and dextrose as a carbohydrate calorie source. The amino acids serve as substrates for protein synthesis, while dextrose provides glucose for cellular energy metabolism via glycolysis and the citric acid cycle. Electrolytes are included to maintain acid-base and fluid balance, and to support enzymatic functions and membrane potentials.
HEPATAMINE 8% is a branched-chain amino acid (BCAA) solution that provides leucine, isoleucine, and valine to correct amino acid imbalances in hepatic encephalopathy. It reduces plasma aromatic amino acids (AAA) and increases BCAA, restoring the BCAA/AAA ratio, which decreases false neurotransmitter synthesis in the brain.
Intravenous infusion. Adult dose: 500 mL to 1000 mL per 24 hours, adjusted to meet protein and calorie requirements. Typical infusion rate: 1.5-2.0 mL/kg/hour, not exceeding 3.0 mL/kg/hour.
Intravenous infusion: 125 mL/hr initially, titrate to achieve positive nitrogen balance; typical adult dose: 125 mL/hr to 250 mL/hr via central line, not to exceed 2 g protein equivalent per kg per day.
None Documented
None Documented
Not applicable as a single entity; amino acids have rapid turnover (minutes to hours) with no terminal half-life. Dextrose has a half-life of 15-20 minutes under steady-state conditions.
Variable; amino acids in HEPATAMINE 8% are cleared rapidly (t1/2 ~10-20 minutes for free amino acids) due to endogenous metabolism. In hepatic failure, half-life may be prolonged (patients with cirrhosis: up to 60 minutes for certain amino acids). Clinical context: supports continuous infusion for stable plasma levels.
Amino acids are metabolized to urea (liver) and CO2; nitrogen is excreted renally as urea (80-90%), with minimal (<5%) biliary/fecal. Dextrose is metabolized to CO2 (exhaled) and water. Electrolytes are excreted renally proportional to intake and homeostasis.
Renal: negligible as intact amino acids; nitrogen waste (urea) excreted renally (80-90% of infused nitrogen). Biliary/fecal: <5%.
Category C
Category C
Amino Acid Solution
Amino Acid Solution